by Combat Cancer | Jun 21, 2025 | News
A study published in The Lancet Oncology in January 2025 revealed that colorectal cancer diagnoses are rising among younger adults worldwide – and England is among the hardest hit. Analysing data up to 2017 from 50 countries, researchers found that in 27 of...
by Combat Cancer | Jun 18, 2025 | News
Statistically, men are nearly four times more likely to be diagnosed with bladder cancer than women. But why is this? In the UK alone, bladder cancer is the seventh most common cancer in men, but only ranks seventeenth in women. This discrepancy has long been...
by Combat Cancer | Jun 7, 2025 | News
Clinical hyperthermia is defined as the therapeutic use of temperature between 41°C to 44°C. While the idea of using heat in medicine isn’t new, what makes clinical hyperthermia especially potent in the treatment of NMIBC is the way in which it enhances the...
by Combat Cancer | May 31, 2025 | News
Combat Medical is proud to announce that our Phase 3 clinical trial of HIVEC®-HEAT for patients with BCG-unresponsive non-muscle-invasive bladder cancer, has received ethical and MHRA (Medicines and Healthcare products Regulatory) approval. HIVEC®-HEAT has also been...
by Combat Cancer | May 24, 2025 | News
New Game-Changing, UK-Based Technological Innovation: The miONCO-Dx Cancer Test An inexpensive blood test that can identify the presence of 12 of the most common and lethal cancers – including cancer of the bladder and bowel – at an early stage, with over 99% accuracy...
Recent Comments